You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AML, minimal residual disease (MRD)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

AML, Adult, Minimal Residual Disease Trial (MRD assessment)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • MRD assessment
  • (no location specified)
Oct 13, 2023

AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • chidamide and azacitidine
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Sep 27, 2023

Acute Myeloid Leukemia Trial in Beijing (DC vaccine)

Recruiting
  • Acute Myeloid Leukemia
  • DC vaccine
  • Beijing, Beijing, China
    Department of hematology
Aug 16, 2021

AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • CD33/CLL1 dual CAR-NK cell
  • +5 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 4, 2023

Minimal Residual Disease Trial in Tianjin (QN-030a, Cyclophosphamid, Fludarabine)

Recruiting
  • Minimal Residual Disease
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Nov 3, 2022

B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)

Recruiting
  • B-Cell Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia
  • Tampa, Florida
    Moffitt Cancer Center
Nov 28, 2023

MRD-tailored Therapy in Newly Diagnosed Multiple Myeloma With

Not yet recruiting
  • Multiple Myeloma
  • Minimal Residual Disease
    • (no location specified)
    Nov 1, 2023

    Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)

    Recruiting
    • Leukemia
    • +19 more
    • CYNK-001
    • Denver, Colorado
    • +9 more
    Sep 9, 2022

    Novel Digital Array PCR for Acute Myeloid Leukemia (AML)

    Recruiting
    • Leukemia, Myeloid, Acute
    • Minimal Residual Disease
      • Chapel Hill, North Carolina
        North Carolina Cancer Hospital (NCCH)
      Feb 2, 2023

      Acute Myeloid Leukemia Trial in Germany (FLYSYN)

      Completed
      • Acute Myeloid Leukemia
      • FLYSYN
      • Tuebingen, Baden-Wuerttemberg, Germany
      • +4 more
      Sep 27, 2021

      Multiple Myeloma Trial (Dexamethasone, Isatuximab, Lenalidomide)

      Not yet recruiting
      • Multiple Myeloma
      • (no location specified)
      Jan 10, 2023

      MRD Detection by NGS in Pediatric B-ALL

      Completed
      • Acute Lymphoblastic Leukemia, Pediatric, Next Generation Sequencing
      • MRD
      • Hangzhou, Zhejiang, China
        The Children's Hospital of Zhejiang University School of Medicin
      Jul 25, 2023

      Using Mass Spectrometry Detecting Minimal Residual Disease in

      Recruiting
      • Multiple Myeloma
        • Tianjin, China
          InsituteHBDH
        Sep 8, 2022

        Minimal Residual Disease, Esophageal Squamous Cell Carcinoma Trial in Guangzhou

        Not yet recruiting
        • Minimal Residual Disease
        • Esophageal Squamous Cell Carcinoma
          • Guangzhou, Guangdong, China
            Guangdong Provincial People's Hospital
          Jun 10, 2023

          Rectal Cancer Patients Based on ctDNA-MRD Technology

          Recruiting
          • Rectal Adenocarcinoma
          • +3 more
          • MRD detection
          • Guangzhou, Guangdong, China
            WeiWei Xiao
          Jul 31, 2023

          Stage II-III Gastric Cancer Trial in Jinan, Qingdao, Yantai (MRD-guided therapy)

          Recruiting
          • Stage II-III Gastric Cancer
          • MRD-guided therapy
          • Jinan, Shandong, China
          • +4 more
          Nov 27, 2023

          Cervical Cancer Trial in Suzhou (Chemoradiotherapy + Adjuvant chemo and Zimberelimab, Chemoradiotherapy (small pelvic) +

          Recruiting
          • Cervical Cancer
          • Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab
          • Chemoradiotherapy (small pelvic) + Zimberelimab
          • Suzhou, Jiangsu, China
            The Affiliated Suzhou Hospital of Nanjing Medical University
          May 14, 2023

          Acute Myeloid Leukemia (AML) or Minimal Residual Disease (MRD Plus) Trial in Pessac, Paris (Human T Lymphoid Progenitor (HTLP)

          Recruiting
          • Acute Myeloid Leukemia (AML) or Minimal Residual Disease (MRD Plus)
          • Human T Lymphoid Progenitor (HTLP) injection
          • Pessac, France
          • +1 more
          Oct 28, 2021

          Multiple Myeloma Trial in United States (Daratumumab, Lenalidomide, Bortezomib)

          Recruiting
          • Multiple Myeloma
          • Ann Arbor, Michigan
          • +3 more
          Jan 19, 2023

          ALL, MRD-positive, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Inotuzumab Ozogamicin)

          Recruiting
          • ALL
          • +2 more
          • Inotuzumab Ozogamicin
          • Suzhou, Jiangsu, China
            The First Affiliated Hospital of Soochow University
          Jul 14, 2023

          Acute Myeloid Leukemia, Adult Trial in Germany (Midostaurin)

          Terminated
          • Acute Myeloid Leukemia, Adult
          • Chemnitz, Germany
          • +3 more
          Jan 20, 2022

          Leukemia, Lymphoma Trial in Houston (Ofatumumab)

          Active, not recruiting
          • Leukemia
          • Lymphoma
          • Houston, Texas
            University of Texas MD Anderson Cancer Center
          Dec 9, 2022

          Minimal Residual Disease Using Multi-omics Approach

          Not yet recruiting
          • Pancreatic Ductal Adenocarcinoma
          • Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test
          • Shanghai, China
            Department of Pancreatic and Hepatobiliary Surgery, Fudan Univer
          Nov 29, 2023

          ctDNA-based Minimal Residual Disease Detection for Resected

          Not yet recruiting
          • Pancreatic Cancer Resectable
          • ctDNA-based MRD detection
          • Shanghai, Shanghai, China
            Ruijin Hospital Affiliated to Shanghai Jiao Tong University Scho
          Jul 29, 2022

          First-Line Serplulimab Plus Chemotherapy in Treatment of

          Not yet recruiting
          • Lung Cancer
          • Serplulimab plus chemotherapy
          • (no location specified)
          May 16, 2023